AbbVie Aktie News

With its diverse product line, AbbVie is a terrific dividend stock with a solid underlying business. Eli Lilly is growing its top line incredibly rapidly and expanding into other therapeutic areas.

Building wealth through dividends requires more than chasing high yields. The path to “getting rich” combines meaningful current income with consistent dividend growth, backed by sustainable business fundamentals.

One of these pharmaceutical leaders overcame a major obstacle and has a strong outlook. The other is actively pushing greater innovation to get around a rapidly approaching patent cliff.

Dividend investing rewards patience. The best dividend stocks don't just pay consistently—they raise payouts year after year, compounding income for shareholders who stay the course.

The wall of worry continues to grow as investors race into 2026. Concentration risk is one that may not get talked about enough.

Bank of America's low payout ratio means this is a dividend you can count on. AbbVie's raking in money with immunology drugs Skyrizi and Rinvoq.

Some valuation metrics suggest that AbbVie is a cheap stock. The company's growth prospects through 2030 look attractive.

AbbVie earns a Strong Buy rating, driven by exceptional execution post-Humira patent cliff and robust 2025 share price outperformance. Skyrizi and Rinvoq are rapidly replacing Humira, delivering 47% and 35% YoY growth in Q3 2025, with patent protection into the 2030s. ABBV's business mix is diversified, with immunology and neuroscience segments together driving double-digit revenue growth and s...